| | Variables | Steatosis CAP ≥238 dB (n = 120) | No steatosis CAP <238 dB (n = 55) | value |
| | Age at LT, years (IQR) | 55 (50–61) | 57 (43–60) | 0.286 | | Age at TE, years (IQR) | 61 (54–65) | 60 (46–65) | 0.131 | | Donor age, years | 60 (48–70) | 57 (41–68) | 0.596 | | Male, % (n) | 75.83 (91) | 52.72 (29) | 0.006 |
| | Cause of liver disease, % (n) | | Autoimmune liver disease | 6.67 (8) | 0.2 (11) | 0.005 | | NAFLD | 0.83 (1) | 0.0 (0) | | Alcoholic liver disease | 37.5 (45) | 18.18 (10) | | HCV | 5.0 (6) | 0.0 (0) | | Others | 50.0 (60) | 61.8 (34) |
| | BMI, kg/m2 (IQR) | 28.76 (23–32) | 26.67 (24–30) | 0.402 |
| | BMI category, % (n) | | Normal <25 | 37.5 (45) | 36.4 (20) | 0.246 | | Overweight 25–29.9 | 23.3 (28) | 40.0 (22) | | Obese ≥30 | 39.2 (47) | 23.6 (13) |
| | Donors BMI, kg/m2 (IQR) | 26.23 (24–28) | 26.03 (24–28) | 0.911 |
| | Donors BMI category, % (n) | | Normal <25 | 40.0 (48) | 34.54 (19) | 0.627 | | Overweight 25–29.9 | 44.2 (53) | 52.73 (29) | | Obese ≥30 | 15.8 (19) | 12.73 (7) |
| | Hypertension, % (n) | 69.75 (83) | 52.73 (29) | 0.041 | | Diabetes, % (n) | 43.70 (52) | 27.27 (15) | 0.063 | | Thrombocytes x109/L | 167 (135–226) | 170 (136–217) | 0.632 | | Glucose, mmol/L (IQR) | 6.4 (6–8) | 5.8 (5–6) | <0.001 | | Total bilirubin, mg/dL (IQR) | 16 (12–21) | 15 (12–26) | 0.558 | | ALT, U/L (IQR) | 29 (20–39) | 26 (17–34) | 0.186 | | AST, U/L (IQR) | 28 (23–40) | 28 (22–37) | 0.598 | | GGT, U/L (IQR) | 41 (24–94) | 31 (17–84) | 0.041 | | Triglyceride, mmol/L (IQR) | 1.37 (1.1–2.0) | 1.03 (0.8–1.4) | <0.001 | | Total cholesterol, mmol/L (IQR) | 5.1 (4.5–5.9) | 4.7 (4.1–5.5) | 0.025 | | LDL, mmol/L (IQR) | 3.1 (2.6–3.7) | 2.8 (2.1–3.5) | 0.016 | | HDL, mmol/L (IQR) | 1.3 (1.1–1.6) | 1.4 (1.2–1.7) | 0.033 | | CRP, mg/L (IQR) | 3.4 (2–6) | 2.3 (1–4) | 0.066 | | LSM, kPa (IQR) | 7.2 (6.0–9.0) | 5.8 (4.5–9.4) | 0.012 |
| | Immunosuppression, % (n) | | Tacrolimus | 67.5 (81) | 76.4 (42) | 0.311 | | Cyclosporine | 32.5 (39) | 21.8 (12) | | Prednisone | 3.3 (4) | 7.3 (4) | | mTOR inhibitor | (0) | 1.8 (1) | | Mycophenolate mofetil | 70.0 (84) | 65.5 (36) | | Azathioprine | (0) | 5.5 (3) |
| | Time from LT to TE, years (IQR) | 4 (3–6) | 3 (2–5) | 0.033 |
|
|
LT, liver transplantation; NAFLD, nonalcoholic fatty liver disease; HCV, hepatitis C virus infection; BMI, body mass index; AST, serum aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; CRP, C-reactive protein; LSM, liver stiffness measurement; TE, transient elastography; CAP, controlled attenuation parameter. |
